New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 11, 2014
09:49 EDTREGNRegeneron sees favorable tax impact from move into Ireland
Regeneron said during its Q4 earnings call earlier that the company is in the process of expanding its manufacturing capabilities into Ireland. "Over the long term with expansion of our international operations, we expect to achieve a tax efficient operating model," the company said, noting the establishment of the new manufacturing facility in Ireland as one step, along with the migration of certain intellectual property in its late stage antibody pipeline to Ireland. The company sees the steps allowing it to get "favorable" tax rates beginning in the 2017 year, it added.
News For REGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 24, 2014
08:04 EDTREGNRegeneron price target raised to $460 from $350 at Canaccord
Subscribe for More Information
October 20, 2014
07:16 EDTREGNAmerican Academy of Ophthalmology to hold annual meeting
AAO Annual Meeting 2014 is being held in Chicago on October 18-21.
07:10 EDTREGNAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
07:02 EDTREGNRegeneron Sanofi begins dosing in Phase 3 study of dupilumab
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the first patients have been dosed in a Phase 3 clinical study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, in adults with moderate-to-severe atopic dermatitis, or AD, that is not adequately controlled with topical AD medications. LIBERTY AD CHRONOS, the first trial in the Phase 3 clinical program for dupilumab, is a randomized, double-blind, placebo-controlled, multi-national study with the primary objective of demonstrating the efficacy of dupilumab in adults with moderate to severe AD when administered concomitantly with topical corticosteroids through 16 weeks.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use